Veytia-Bucheli, José Ignacio
Jiménez-Vargas, Juana María
Melchy-Pérez, Erika Isabel
Sandoval-Hernández, Monserrat Alba
Possani, Lourival Domingos
Rosenstein, Yvonne http://orcid.org/0000-0003-4040-4256
Funding for this research was provided by:
Consejo Nacional de Ciencia y Tecnología (SEP-CONACYT 237864, SEP-CONACYT 220990)
Article History
Received: 1 June 2018
Accepted: 2 August 2018
First Online: 14 August 2018
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The Vm24 peptide and its use are protected by an international patent application WO2008139243 A1 in the name of Universidad Nacional Autónoma de Mexico (UNAM). The same subject was protected in several countries. In addition, a license was granted to a Mexican pharmaceutical company for commercial exploitation; however, the authors kept the right to continuing research in the field involving this peptide. The financing of this work came from the declared funding institutions only. No other possible conflicts of interest are involved.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.